A novel way in anti-tumor therapy has been demonstrated by immunomodulatory agents blocking the programmed cell death protein 1(PD-1)/programmed death 1 ligand 1(PD-L1) pathway [20]. This evidence concerns the gene PDCD1 and neoplasm.